Nvidia and TSMC to unveil first domestic wafer for Blackwell chips, Axios reports
Sarah Aebersold, Chief Human Resources Officer at BioLife Solutions Inc (NASDAQ:BLFS), a $1.33 billion market cap company, sold 188 shares of the company’s common stock on October 9, 2025. The shares were sold at $27.36, for a total transaction value of $5,143. The transaction occurred as the stock trades near its 52-week high of $29.55, having gained approximately 24% over the past six months.
Following the transaction, Aebersold directly owns 77,169 shares of BioLife Solutions. The sale was executed under a pre-arranged Rule 10b5-1 trading plan to cover tax obligations related to the vesting of restricted stock. According to InvestingPro analysis, the stock currently appears overvalued, with volatile price movements being a key characteristic. For deeper insights into insider trading patterns and comprehensive financial analysis, InvestingPro offers detailed reports covering 1,400+ US stocks, including BLFS.
In other recent news, BioLife Solutions reported its second-quarter 2025 financial results, revealing a significant earnings per share (EPS) miss but a positive revenue outcome. The company posted an EPS of -$0.33, which fell short of the expected -$0.03, while revenue reached $25.42 million, marking a 29% year-over-year increase and surpassing analyst expectations. In a strategic move, BioLife Solutions sold its cold chain logistics subsidiary, SAVSU Cleo Technologies, to Peli BioThermal for $25.5 million in cash, subject to certain adjustments. Analyst firms have responded to these developments, with KeyBanc reiterating its Overweight rating on BioLife Solutions, citing potential growth avenues and a revenue target exceeding $250 million by 2030. H.C. Wainwright also raised its price target for the company to $32 from $30, maintaining a Buy rating. Furthermore, at its 2025 annual stockholders meeting, BioLife Solutions re-elected all board members, approved executive compensation, and ratified Grant Thornton LLP as the independent auditor for the fiscal year ending December 31, 2025. These updates reflect ongoing strategic and financial maneuvers by BioLife Solutions as it navigates its growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.